MCK · Full Picture

MCKESSON CORP — the full picture

Earnings window · 2026-07-15 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Opioid Litigation · Litigation & settlementsPriority 80
    -7.6% liability; 3 forward row(s); structured_verified
    The Distributors agreed to a $7.9 billion Settlement to be paid by 2038, with a minimum of % of the payments required to remediate the opioid epidemic (percentage redacted).
  2. Capital Return Program · Buybacks & dividendsPriority 79
    -7.0% cash; 3 sources (news, press_release, sec_filing); 3 forward row(s); structured_verified
    On April 29, 2026, the Board of Directors approved the Company to repurchase up to an additional $5.0 billion of common stock.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 74
    +14.7% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Oncology & Multispecialty segment revenues: $14.2 billion, increased 33%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.
  4. Liquidity and Debt Position · Debt, leverage & refinancingPriority 71
    +7.3% cash (realized); structured_verified
    On April 24, 2026 the Company established a $5.0 billion senior unsecured revolving credit facility maturing in April 2031 (the 2026 Credit Facility)
  5. Guidance / Outlook · Guidance & outlookPriority 63
    2 sources (news, press_release); 2 forward row(s); quote_verified
    Fiscal 2027 Adjusted Earnings per Diluted Share guidance raised to a range of $44.20 to $45.00 from the previous range of $43.80 to $44.60.
  6. FX / Currency Impact · Currency / FXPriority 59
    1 forward row(s); quote_verified
    During July 2026 the Company terminated C$6.5 billion of cross-currency swaps designated as net investment hedges and entered into cross-currency swaps with a total notional amount of C$7.5 billion maturing in July 2027 through July 2030
  7. Oncology Specialty Demand · Demand, orders & backlogPriority 56
    +3.4% revenue (realized); 2 sources (news, sec_filing); quote_verified
    Oncology & Multispecialty revenues increased $3.6 billion or 33% for the three months ended June 30, 2026 compared to the same prior year period primarily driven by higher specialty pharmaceutical sales in provider solutions.
  8. Specialty Distribution Growth · Supply chain & operationsPriority 53
    quote_verified
    Oncology & Multispecialty Segment Operating Profit: $325 million; Adjusted Segment Operating Profit: $405 million, an increase of 41%.
  9. Market Demand Trends · Demand, orders & backlogPriority 51
    2 sources (press_release, sec_filing); quote_verified
    Revenues increased for the three months ended June 30, 2026 primarily due to market growth in our North American Pharmaceutical segment, including higher volumes from institutional healthcare providers and retail national account customers, and growth in our Oncology & Multispecialty segment primarily due to higher specialty pharmaceutical sales.
  10. Liquidity and Debt Position · Liquidity & cash positionPriority 50
    1 forward row(s); quote_verified
    On June 9, 2026, McKesson established a secured Term Loan B facility of $2.25 billion in support of the planned separation of Medical-Surgical Solutions segment.
  11. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 49
    2 sources (news, press_release); 2 forward row(s); quote_verified
    On June 1, 2026, McKesson sold an approximately 13% minority interest in its Medical-Surgical Solutions business to Apollo Funds for $1.25 billion.
  12. Medical-Surgical Separation · UnclassifiedPriority 49
    +1.4% cash (realized); 2 sources (news, sec_filing); 1 forward row(s); quote_verified
    On June 1, 2026, Apollo Funds invested approximately $1.25 billion in convertible preferred equity of the Medical-Surgical Solutions business to acquire an approximately 13% minority ownership interest.

Threads by pillar

Revenue & Demand Priority 87 · 7 threads

Costs & Margins Priority 74 · 6 threads

Capital & Balance Sheet Priority 89 · 5 threads

Strategy & Portfolio Priority 49 · 1 thread

Legal, Regulatory & Policy Priority 83 · 2 threads

Guidance & Outlook Priority 63 · 1 thread

Macro & Market Conditions Priority 60 · 2 threads

Unclassified Priority 71 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
liability-7.6%+7.6%-3.6%
cash-7.0%+7.0%+4.4%
operating_income-2.1%+2.1%-0.1%
net_income+0.2%+0.2%-0.3%
revenue——+18.1%